Javelin Biotech

Drug Analysis Technology

Javelin Biotech is developing predictive drug discovery platforms that merge human tissue chips with computational biology and machine learning to improve preclinical R&D productivity and reduce reliance on animal studies. The company's first product, a pharmacokinetics (PK) platform, is developed in partnership with Pfizer. This platform can deliver clinical predictions that are 33% more accurate, 10x faster, and cheaper than rat PK studies, potentially replacing over one million animal-based PK studies per year. Javelin Biotech is also developing platforms for other areas of drug discovery, including toxicology and efficacy. The company's goal is to create a comprehensive suite of predictive drug discovery platforms that will help bring new drugs to market faster and more cheaply.